<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267681</url>
  </required_header>
  <id_info>
    <org_study_id>Ufuk University</org_study_id>
    <nct_id>NCT02267681</nct_id>
  </id_info>
  <brief_title>Opioid Effects on Cognitive Function Following Colonoscopy</brief_title>
  <official_title>The Effects of Fentanyl and Alfentanil as an Adjunct to Propofol on Cognitive Functions for Sedation in Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perihan Ekmekçi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ufuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the effects of fentanyl and alfentanil on postprocedural cognitive&#xD;
      function in elective endoscopy.&#xD;
&#xD;
      150 patients will be enrolled in the study. Patients meeting eligibility criteria will be&#xD;
      randomly allocated to three groups.&#xD;
&#xD;
      The patients in Group A will be given propofol and alfentanil. The patients in Group F will&#xD;
      be given propofol and fentanyl. Group P is designated as the control group and the patients&#xD;
      will be given propofol for sedation.&#xD;
&#xD;
      Awareness, vital signs and pain will be evaluated. Side effects will be recorded. Patient and&#xD;
      endoscopist satisfaction will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we aimed to compare the effects of sedation provided by propofol with the&#xD;
      addition of the short-acting opioid alfentanil and long-acting opioid fentanyl on cognitive&#xD;
      functions, pain, side effects during the procedure and the endoscopist and patient&#xD;
      satisfaction.&#xD;
&#xD;
      Following the approval of Kırıkkale University ethics committee, 150 patients ages between 18&#xD;
      and 65 ASA I-III scheduled for elective endoscopy and colonoscopy will be enrolled in the&#xD;
      study.&#xD;
&#xD;
      After obtaining written informed consent, APAIS (The Amsterdam Preoperative Anxiety and&#xD;
      Information Scale) and MMTS (Mini Mental Test Scoring) tests will given to patients.&#xD;
      Following TDT (Trieger Dot Test) and DSST (Digit Symbol Substitution Test), the patients will&#xD;
      be randomly allocated to either Propofol-Alfentanil (Group A), Propofol-Fentanyl (Group F) or&#xD;
      Propofol-Control (Group P) which consists of 50 patients each.&#xD;
&#xD;
      The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading&#xD;
      dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain&#xD;
      Scale) is greater than 3 or the patients can not tolerate the procedure.&#xD;
&#xD;
      The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading&#xD;
      dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is&#xD;
      greater than 3 or the patients could not tolerate the procedure.&#xD;
&#xD;
      Group P is designated as the control group and the patients will be given 100mcg/kg/min&#xD;
      infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg&#xD;
      propofol additional bolus will be given whenever the patients can not tolerate the procedure&#xD;
      or FPS is greater than 3.&#xD;
&#xD;
      BIS values, mean arterial pressures, heart rates, peripheral oxygen saturations will be&#xD;
      recorded in all three groups. FPS and VAS (Visual Analogue Scale) values will be evaluated.&#xD;
&#xD;
      Patients with intraprocedural desaturation, hypo- or hypertension, brady- or tachycardia,&#xD;
      nausea, vomiting and apnea will be recorded. Total amounts of drugs administered will be&#xD;
      recorded.&#xD;
&#xD;
      Infusions will be ceased at the end of the procedure and the time for OAAS/S to exceed 3 will&#xD;
      be recorded and TDT and DSST will be repeated at 5, 15 and 30th minutes. Patient and&#xD;
      endoscopist satisfaction will be evaluated in all cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive dysfunction</measure>
    <time_frame>during the 30 minutes after the termination of the procedure</time_frame>
    <description>as evaluated using Trieger dot test,Mini mental test and Digit symbol substitution test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient and endoscopist satisfaction</measure>
    <time_frame>following the procedure</time_frame>
    <description>as evaluated using a 5-point Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>during the 30 minutes after the termination of the procedure</time_frame>
    <description>as evaluated using VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>during the 30 minutes after the termination of the procedure</time_frame>
    <description>hypotension, hypertension, bradycardia, tachycardia, apnea, nausea and vomiting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Digestive System Diseases</condition>
  <condition>Disorientation</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Intravenous fentanyl for sedation/analgesia</description>
    <arm_group_label>Group F</arm_group_label>
    <other_name>Talinat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfentanil</intervention_name>
    <description>Intravenous alfentanyl for sedation/analgesia</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Rapifen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous propofol for sedation</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group P</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages between 18-65&#xD;
&#xD;
          -  American Society of Anesthesiologists classification I-III&#xD;
&#xD;
          -  Patients scheduled to undergo elective colonoscopy or endoscopy and colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 or older than 65&#xD;
&#xD;
          -  Mini mental test score &lt; 26&#xD;
&#xD;
          -  APAIS (The Amsterdam Preoperative Anxiety and Information Scale) &gt;10&#xD;
&#xD;
          -  Serious systemic disease&#xD;
&#xD;
          -  Neuropsychiatric disorder&#xD;
&#xD;
          -  Chronic alcohol abuse&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  History of anesthesia in the last 7 days&#xD;
&#xD;
          -  Known allergy to study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perihan Ekmekçi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFUK UNIVERSITY FACULTY OF MEDICINE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ufuk University Dr Rıdvan Ege Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Froehlich F, Gonvers JJ, Fried M. Conscious sedation, clinically relevant complications and monitoring of endoscopy: results of a nationwide survey in Switzerland. Endoscopy. 1994 Feb;26(2):231-4.</citation>
    <PMID>8026371</PMID>
  </reference>
  <reference>
    <citation>Türk HŞ, Aydoğmuş M, Unsal O, Köksal HM, Açik ME, Oba S. Sedation-analgesia in elective colonoscopy: propofol-fentanyl versus propofol-alfentanil. Braz J Anesthesiol. 2013 Jul-Aug;63(4):352-7. doi: 10.1016/j.bjane.2012.07.007. Epub 2013 Aug 13.</citation>
    <PMID>24565243</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ufuk University</investigator_affiliation>
    <investigator_full_name>Perihan Ekmekçi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Confusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Alfentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

